A recombinant human IgM promotes myelin repair after a single, very low dose

Arthur E. Warrington, Allan J. Bieber, Bogoljub Ciric, Larry R Pease, Virginia Van Keulen, Moses Rodriguez

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

A recombinant human monoclonal IgM, rHIgM22, promotes the synthesis of new myelin when used to treat several animal models of demyelination. rHIgM22 binds to myelin and the surface of oligodendrocytes and accumulates at central nervous system lesions in vivo. The minimal dose of monoclonal IgM required to promote remyelination has a direct bearing on the proposed mechanism of action. A dose ranging study using rHIgM22 was performed in mice with chronic virus-induced demyelination, a model of chronic progressive multiple sclerosis. The lowest tested dose of rHIgM22 effective at promoting spinal cord remyelination was a single 500-ng intraperitoneal bolus injection. A time course study of spinal cord repair performed in chronically demyelinated mice revealed that remyelination plateaued by 5 weeks following treatment with rHIgM22. Two doses of rHIgM22 spaced 5 weeks apart did not increase the extent of remyelination over a single dose. The half-life of rHIgM22 in the mouse systemic circulation was determined to be 15 hr; the human IgM serum concentration was close to zero by 48 hr following antibody administration. We propose that the specificity of rHIgM22 for myelin on living tissue targets the antibody to demyelinated lesions, initiating a long-term reparative effect on the central nervous system.

Original languageEnglish (US)
Pages (from-to)967-976
Number of pages10
JournalJournal of Neuroscience Research
Volume85
Issue number5
DOIs
StatePublished - Apr 2007

Fingerprint

Myelin Sheath
Immunoglobulin M
Demyelinating Diseases
Central Nervous System
Spinal Cord Regeneration
Chronic Progressive Multiple Sclerosis
Antibodies
Oligodendroglia
Intraperitoneal Injections
Half-Life
Spinal Cord
Animal Models
Viruses
Serum
Therapeutics

Keywords

  • Multiple sclerosis
  • Oligodendrocyte
  • Spinal cord repair
  • Theiler's murine encephalomyelitis virus

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Warrington, A. E., Bieber, A. J., Ciric, B., Pease, L. R., Van Keulen, V., & Rodriguez, M. (2007). A recombinant human IgM promotes myelin repair after a single, very low dose. Journal of Neuroscience Research, 85(5), 967-976. https://doi.org/10.1002/jnr.21217

A recombinant human IgM promotes myelin repair after a single, very low dose. / Warrington, Arthur E.; Bieber, Allan J.; Ciric, Bogoljub; Pease, Larry R; Van Keulen, Virginia; Rodriguez, Moses.

In: Journal of Neuroscience Research, Vol. 85, No. 5, 04.2007, p. 967-976.

Research output: Contribution to journalArticle

Warrington, AE, Bieber, AJ, Ciric, B, Pease, LR, Van Keulen, V & Rodriguez, M 2007, 'A recombinant human IgM promotes myelin repair after a single, very low dose', Journal of Neuroscience Research, vol. 85, no. 5, pp. 967-976. https://doi.org/10.1002/jnr.21217
Warrington, Arthur E. ; Bieber, Allan J. ; Ciric, Bogoljub ; Pease, Larry R ; Van Keulen, Virginia ; Rodriguez, Moses. / A recombinant human IgM promotes myelin repair after a single, very low dose. In: Journal of Neuroscience Research. 2007 ; Vol. 85, No. 5. pp. 967-976.
@article{c341a00d47e247e8b990adbf3c4fd70d,
title = "A recombinant human IgM promotes myelin repair after a single, very low dose",
abstract = "A recombinant human monoclonal IgM, rHIgM22, promotes the synthesis of new myelin when used to treat several animal models of demyelination. rHIgM22 binds to myelin and the surface of oligodendrocytes and accumulates at central nervous system lesions in vivo. The minimal dose of monoclonal IgM required to promote remyelination has a direct bearing on the proposed mechanism of action. A dose ranging study using rHIgM22 was performed in mice with chronic virus-induced demyelination, a model of chronic progressive multiple sclerosis. The lowest tested dose of rHIgM22 effective at promoting spinal cord remyelination was a single 500-ng intraperitoneal bolus injection. A time course study of spinal cord repair performed in chronically demyelinated mice revealed that remyelination plateaued by 5 weeks following treatment with rHIgM22. Two doses of rHIgM22 spaced 5 weeks apart did not increase the extent of remyelination over a single dose. The half-life of rHIgM22 in the mouse systemic circulation was determined to be 15 hr; the human IgM serum concentration was close to zero by 48 hr following antibody administration. We propose that the specificity of rHIgM22 for myelin on living tissue targets the antibody to demyelinated lesions, initiating a long-term reparative effect on the central nervous system.",
keywords = "Multiple sclerosis, Oligodendrocyte, Spinal cord repair, Theiler's murine encephalomyelitis virus",
author = "Warrington, {Arthur E.} and Bieber, {Allan J.} and Bogoljub Ciric and Pease, {Larry R} and {Van Keulen}, Virginia and Moses Rodriguez",
year = "2007",
month = "4",
doi = "10.1002/jnr.21217",
language = "English (US)",
volume = "85",
pages = "967--976",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - A recombinant human IgM promotes myelin repair after a single, very low dose

AU - Warrington, Arthur E.

AU - Bieber, Allan J.

AU - Ciric, Bogoljub

AU - Pease, Larry R

AU - Van Keulen, Virginia

AU - Rodriguez, Moses

PY - 2007/4

Y1 - 2007/4

N2 - A recombinant human monoclonal IgM, rHIgM22, promotes the synthesis of new myelin when used to treat several animal models of demyelination. rHIgM22 binds to myelin and the surface of oligodendrocytes and accumulates at central nervous system lesions in vivo. The minimal dose of monoclonal IgM required to promote remyelination has a direct bearing on the proposed mechanism of action. A dose ranging study using rHIgM22 was performed in mice with chronic virus-induced demyelination, a model of chronic progressive multiple sclerosis. The lowest tested dose of rHIgM22 effective at promoting spinal cord remyelination was a single 500-ng intraperitoneal bolus injection. A time course study of spinal cord repair performed in chronically demyelinated mice revealed that remyelination plateaued by 5 weeks following treatment with rHIgM22. Two doses of rHIgM22 spaced 5 weeks apart did not increase the extent of remyelination over a single dose. The half-life of rHIgM22 in the mouse systemic circulation was determined to be 15 hr; the human IgM serum concentration was close to zero by 48 hr following antibody administration. We propose that the specificity of rHIgM22 for myelin on living tissue targets the antibody to demyelinated lesions, initiating a long-term reparative effect on the central nervous system.

AB - A recombinant human monoclonal IgM, rHIgM22, promotes the synthesis of new myelin when used to treat several animal models of demyelination. rHIgM22 binds to myelin and the surface of oligodendrocytes and accumulates at central nervous system lesions in vivo. The minimal dose of monoclonal IgM required to promote remyelination has a direct bearing on the proposed mechanism of action. A dose ranging study using rHIgM22 was performed in mice with chronic virus-induced demyelination, a model of chronic progressive multiple sclerosis. The lowest tested dose of rHIgM22 effective at promoting spinal cord remyelination was a single 500-ng intraperitoneal bolus injection. A time course study of spinal cord repair performed in chronically demyelinated mice revealed that remyelination plateaued by 5 weeks following treatment with rHIgM22. Two doses of rHIgM22 spaced 5 weeks apart did not increase the extent of remyelination over a single dose. The half-life of rHIgM22 in the mouse systemic circulation was determined to be 15 hr; the human IgM serum concentration was close to zero by 48 hr following antibody administration. We propose that the specificity of rHIgM22 for myelin on living tissue targets the antibody to demyelinated lesions, initiating a long-term reparative effect on the central nervous system.

KW - Multiple sclerosis

KW - Oligodendrocyte

KW - Spinal cord repair

KW - Theiler's murine encephalomyelitis virus

UR - http://www.scopus.com/inward/record.url?scp=33947507646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947507646&partnerID=8YFLogxK

U2 - 10.1002/jnr.21217

DO - 10.1002/jnr.21217

M3 - Article

C2 - 17304578

AN - SCOPUS:33947507646

VL - 85

SP - 967

EP - 976

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 5

ER -